Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone844-362-2566
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.10 million
Profitability
Miscellaneous
Employees100
Next Earnings Date5/23/2019 (Estimated)
OptionableOptionable
Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions
What is Obalon Therapeutics' stock symbol?
Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."
How were Obalon Therapeutics' earnings last quarter?
Obalon Therapeutics Inc (NASDAQ:OBLN) released its earnings results on Friday, February, 22nd. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.08. The business earned $2.04 million during the quarter, compared to analyst estimates of $2.10 million. Obalon Therapeutics had a negative net margin of 147.30% and a negative return on equity of 100.59%. View Obalon Therapeutics' Earnings History.
When is Obalon Therapeutics' next earnings date?
What price target have analysts set for OBLN?
5 brokers have issued twelve-month target prices for Obalon Therapeutics' stock. Their forecasts range from $1.00 to $3.50. On average, they expect Obalon Therapeutics' share price to reach $2.35 in the next twelve months. This suggests a possible upside of 487.5% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.
What is the consensus analysts' recommendation for Obalon Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.
What are Wall Street analysts saying about Obalon Therapeutics stock?
Here are some recent quotes from research analysts about Obalon Therapeutics stock:
- 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (5/17/2019)
- 2. Northland Securities analysts commented, "We believe Option #3 is most likely. For sure, the debt can be renegotiated. It would be interesting to see how the covenant triggers change and what analyses" would facilitate a re-evaluation of assumptions inherent in the original contract." (4/11/2019)
Has Obalon Therapeutics been receiving favorable news coverage?
News stories about OBLN stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Obalon Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Obalon Therapeutics' key competitors?
Some companies that are related to Obalon Therapeutics include Nephros (NEPH), PAVmed (PAVM), Alliqua Biomedical (ALQA), Avinger (AVGR), Neovasc (NVCN), SANUWAVE Health (SNWV), DarioHealth (DRIO), BRAINSWAY LTD/S (BWAY), Hancock Jaffe Laboratories (HJLI), Lianluo Smart (LLIT), Interpace Diagnostics Group (IDXG), Valeritas (VLRX), Atossa Genetics (ATOS), Restoration Robotics (HAIR) and Biostage (BSTG).
What other stocks do shareholders of Obalon Therapeutics own?
Who are Obalon Therapeutics' key executives?
Obalon Therapeutics' management team includes the folowing people:
- Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
- Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
- Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
- Mr. Mark C. Brister, Chief Technology Officer (Age 57)
- Ms. Daina Schmidt, VP of Marketing
When did Obalon Therapeutics IPO?
(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.
How do I buy shares of Obalon Therapeutics?
Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obalon Therapeutics' stock price today?
One share of OBLN stock can currently be purchased for approximately $0.40.
How big of a company is Obalon Therapeutics?
Obalon Therapeutics has a market capitalization of $9.60 million and generates $9.10 million in revenue each year. The company earns $-37,380,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis. Obalon Therapeutics employs 100 workers across the globe.
What is Obalon Therapeutics' official website?
How can I contact Obalon Therapeutics?
Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]
MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
